Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMES: Metabolic Surgery vs Incretin-Based Therapies for MASH
NCT06374875Phase 4Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Jul 2024
- Primary completion
- May 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 4, randomised, single-blind trial in metabolic dysfunction-associated steatohepatitis (MASH), Liver Fibrosis (LF) and obesity (2 arms), sponsored by Cleveland Clinic. Primary endpoint: Improvement of at least 1 fibrosis stage of the Kleiner fibrosis classification and no worsening of MASH at 2 years. Started Jul 2024; status: recruiting.
02
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis (LF)obesity
Beyond the preview
Go deeper on NCT06374875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374875.